Advertisement
The company also announces that Mr. Yat Ming Chu has resigned as the VicePresident of Sales and Marketing, together with the departure of Mr. Eric WangLam Cheung as Vice President of Investor Relations.
Advertisement
Mark Chen joins Simcere from the pharmaceutical company Merck & Co'sinternational arm, Merck Sharp & Dohme, where he was most recently theBusiness Unit Director based in Taiwan. Prior to Merck, Mark held seniormanagement roles at Procter & Gamble Greater China and at Softchina VentureGroup, a venture capital firm.
Mr. Boxing Zha joined Simcere in 1996 with over 12 years of hospital salesexperience and most recently served as General Manager of Simcere Shanghai.Mr. Dasheng Sun joined Simcere in 2001 and was formerly the General Manager ofBusiness Development with extensive experience in both commercial and retailpharmaceutical sales.
Mr. Jinsheng Ren, Chairman and CEO of Simcere, commented, "On behalf ofthe board, I want to express our sincere gratitude to Mr. Chu for hiscontribution and dedication, which spans over ten years at Simcere, and forMr. Cheung's hard work during and beyond our IPO last year. I wish them boththe very best for the future."
Mr. Jinsheng Ren added: "We are delighted to welcome Mr. Chen to our team.Mr. Chen brings valuable experience in sales and marketing from globalhealthcare and consumer businesses and will bring additional internationalexpertise to the company's sales and marketing strategy. I am confident thathe will help us grow our business both domestically and internationally. Weare very pleased to promote Mr. Sun and Mr. Zha to the VP of Sales positionand we believe, with their many years of valuable industry experience andsolid performance within Simcere, that they will be successful in their newresponsibilities as we sharpen our focus in targeting more hospitals andpharmacies across China."
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leadingmanufacturer and supplier of branded generic pharmaceuticals and manufacturerof the patented anti-cancer biotech product Endu in the rapidly growing Chinamarket. In recent years, Simcere has focused its strategy on the developmentof first-to-market generic and innovative pharmaceuticals, and has introduceda first-to-market generic stroke management medication under the brand nameBicun and an innovative anti-cancer medication under the brand name Endu.Simcere currently manufactures and sells more than 50 pharmaceutical productsincluding antibiotics, anti-cancer medication and stroke management medicationand is the exclusive distributor of three additional pharmaceuticals that aremarketed under its brand names. Simcere concentrates its research anddevelopment efforts on the treatment of diseases with high incidence and/ormortality rates and for which there is a clear demand for more effectivepharmacotherapy such as cancer, strokes, osteoporosis and infectious diseasesand currently has more than 12 pipeline products. For more information aboutSimcere Pharmaceutical Group, please visit www.simcere.com.
Contact:
Michael Guerin of Brunswick Group
+1-212-333-3810
SOURCE Simcere Pharmaceutical Group
